Methicillin

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

Retrieved on: 
Friday, September 22, 2023
Priority review, Food and Drug Administration Safety and Innovation Act, Innovation Act, IV, Prevalence, Amputation, Diabetes, QIDP, Methicillin, S. aureus, Methicillin-resistant Staphylococcus aureus, Infection, Act, MRSA, NDA, Fast Track, Osteomyelitis, ABSSSI, GAIN, Diabetic foot infection, Patient, Ulcer, Disease, DFI, Mortality, Toxic shock syndrome, Bacteria, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gram-positive bacteria, Food, Pharmaceutical industry, FDASIA

Oral contezolid and intravenous (IV) contezolid acefosamil are currently being studied in a global Phase 3 clinical trial in treatment of patients with DFI.

Key Points: 
  • Oral contezolid and intravenous (IV) contezolid acefosamil are currently being studied in a global Phase 3 clinical trial in treatment of patients with DFI.
  • Both products were previously granted QIDP designation and Fast Track status in 2018 for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
  • With excellent microbiological activity against common Gram-positive bacteria, contezolid and contezolid acefosamil are well positioned to benefit DFI patients, particularly due to methicillin-resistant Staphylococcus aureus (MRSA).
  • "We believe that MicuRx can offer an important new choice for DFI treatment with flexibility of oral and IV formulations."

Plants of the boreal forest: Using traditional Indigenous medicine to create modern treatments

Retrieved on: 
Wednesday, July 26, 2023
Cornus, Heart, Radical, Taxus, Echinacea, Methicillin, Tellimagrandin I, Methicillin-resistant Staphylococcus aureus, Infection, Paclitaxel, Indigenous peoples, Research, Medicine, Inflammation, Rhizome, Populus, Psoriasis, Plant, SARM, Oxidative stress, Poplar River First Nation, Population, Developed country, Laboratory, Immune system, First Nations, Knowledge, Glycine mollis, Cauchy stress tensor, Ecology, Health, Family, Aralia, Pharmaceutical industry, Silviculture, Medicinal plants, Indigenous

This article is part of La Conversation Canada’s series The boreal forest: A thousand secrets, a thousand dangers La Conversation Canada invites you to take a virtual walk in the heart of the boreal forest.

Key Points: 
  • This article is part of La Conversation Canada’s series The boreal forest: A thousand secrets, a thousand dangers La Conversation Canada invites you to take a virtual walk in the heart of the boreal forest.
  • These products are deeply rooted in ancestral knowledge and traditions and are passed down from generation to generation in Indigenous communities.
  • Some molecules isolated from plants have become major therapeutic agents in modern medicine.

The boreal forest: a source of natural medicines

    • The LASEVE team has studied a number of plant species from the boreal forest that are used in traditional Indigenous medicine.
    • The bunchberry (Cornus canadensis), for example, is traditionally used as an antiviral remedy by First Nations peoples.
    • Our research on this species has shown that the leaf extract has therapeutic activity against herpes simplex type 1 (HSV-1), a virus responsible for cold sores.
    • This activity is due to the high content of phenolic compounds in the extract.

Adaptogenic plants from the boreal forest

    • Adaptogenic plants are attracting attention from researchers as a response to this challenge.
    • These plants have a regulating effect, particularly on our immune system, which improves the body’s ability to adapt to environmental stress.
    • Echinacea, astragalus and the famous ginseng are just a few examples of adaptogenic plants.
    • In conclusion, our research group has been working for several years to explore the therapeutic potential hidden in boreal forest plants.

Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, June 8, 2023
Biologics license application, US Foods, Community-acquired pneumonia, MSSA, S. aureus, Methicillin, CAP, Infection, MRSA, Clinical trial, Pharmacokinetics, Cystic fibrosis, Hospital-acquired pneumonia, Melinda French Gates, Staphylococcus, Immunotherapy, AstraZeneca, Staphylococcus aureus, Trial of the century, DE, Pseudomonas aeruginosa, Apex, Phase 10, Development, CFF, Bill & Melinda Gates Foundation, Expense, Patient, Immunoglobulin G, Met, VAP, Administration, Cystic Fibrosis Foundation, Ventilator-associated pneumonia, LOS, Bacteria, Gallium, Research, Gates, FDA, HAP, BLA, ICU, Pneumonia, Safety, Pharmaceutical industry, Cryptocurrency, COVID-19, Kermode

LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2023.

Key Points: 
  • LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2023.
  • “Our first quarter results demonstrate the continued progress and momentum of Aridis Pharmaceuticals.
  • First Quarter 2023 Financial Results:
    Cash: Total cash, cash equivalents and restricted cash as of March 31, 2023, were approximately $1.8 million.
  • Change in Other Comprehensive Income: Change in other comprehensive income increased by approximately $861,000 for the quarter ended March 31, 2023 from $0 for the quarter ended March 31, 2022.

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Retrieved on: 
Friday, April 28, 2023
Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Aureus, Neuroblastoma, Menopause, Letter, US Foods, Methicillin-resistant Staphylococcus aureus, Bank statement, Infection, USFDA, CMC, MRSA, NGS, Liquid biopsy, Methicillin, Lead, Staphylococcus, Staphylococcus aureus, ABSSSI, Euronext Paris, Patient, Investment, Transaction, JD, Distell Group Limited, Diagnosis, IND, US FDA, Food, Pharmaceutical industry, Cryptocurrency

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2022, and provided an update on clinical and corporate developments.

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2022, and provided an update on clinical and corporate developments.
  • Mr. Darren Lui, Chief Executive Officer and Executive Director of Aptorum Group, commented “Aptorum’s operational plans remain on track.
  • Aptorum Group reported a net loss of $11.5 million in 2022, as compared to $27.1 million in 2021.
  • Aptorum Group reported $5.0 million of cash and restricted cash as of December 31, 2022 compared to $8.3 million as of December 31, 2021.

Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use

Retrieved on: 
Thursday, March 16, 2023
United States patent law, EVP, Ulcerative colitis, SAN, Patent, GI, Apoptosis, Human, Methicillin, MRSA, Pharmaceutical industry

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that the US Patent and Trademark Office (USPTO) has issued US Patent No. 11,579,703 titled “Caspase Inhibitors and Methods of Use Thereof.”

Key Points: 
  • 11,579,703 titled “Caspase Inhibitors and Methods of Use Thereof.”
    We believe this key patent provides broad coverage for Histogen’s portfolio of highly selective and orally active anti-inflammatory caspase inhibitors, including CTS-2090.
  • This patent includes information that CTS-2090 has demonstrated potent oral activity in a well characterized model of ulcerative colitis.
  • It builds upon Histogen’s growing proprietary caspase inhibitor portfolio that includes the US patent No.
  • This previously issued patent discloses a broad class of novel pan-caspase inhibitors with unique chemical properties,” stated Alfred Spada, EVP and Chief Scientific Officer of Histogen.

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Methicillin-resistant Staphylococcus aureus, NYSE, Infection, VRE, Daptomycin, Phenotype, Enterococcus-1 RNA motif, Methicillin, MRSA, Vancomycin, Oxacillin, Vaccine, Antibiotics, Oragene

Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.

Key Points: 
  • Lantibiotics are a novel class of antibiotics with the potential to treat serious, life-threatening infections.
  • Oragenics’ lantibiotics platform is focused on the development of new antibiotics effective against certain pathogens including vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA).
  • Oragenics is focused on addressing this unmet medical need through its novel lantibiotics platform, and the results of its work with Linnaeus Bioscience advance Oragenics’ long-term mission to become a provider of effective treatments for infectious diseases.
  • Oragenics remains committed to fighting infectious diseases through the development of its lantibiotics pipeline against MRSA and VRE pathogens.

Histogen Reports Year-End 2022 Results and Provides Business Update

Retrieved on: 
Thursday, March 9, 2023
Methicillin, Trial of the century, IND, Conatus, Acquisition, HST, Medication, Pfizer, Enzyme, ABSSSI, Knee, SAN, Mortgage assumption, Research, NSF, Patient, Extracellular matrix, CCM, Interim, Staphylococcus aureus, EVP, Apoptosis, Cartilage, CSO, Inflammation, COVID-19, Insurance, Caspase, Toxicology, Sale, MRSA, Safety, Pharmaceutical industry, Cryptocurrency, Allergan

Twelve Months Ended December 31, 2022 and 2021

Key Points: 
  • Twelve Months Ended December 31, 2022 and 2021
    For the years ended December 31, 2022 and 2021, we recognized license revenues of $3.8 million and $27 thousand, respectively.
  • For the years ended December 31, 2022 and 2021, we recognized grant revenue of $0 and $0.1 million, respectively.
  • Research and development expenses for the years ended December 31, 2022 and 2021 were $5.0 million and $8.5 million, respectively.
  • General and administrative expenses for the years ended December 31, 2022 and 2021 were $9.4 million and $7.8 million, respectively.

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Retrieved on: 
Friday, March 3, 2023
Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Aureus, JT Group Limited, Staphylococcus, ABSSSI, US FDA, Infection, Staphylococcus aureus, US Food Sovereignty Alliance, Euronext Paris, MRSA, Methicillin, Pharmaceutical industry, IND

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions with the US Food and Drug Administration (“US FDA”).

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions with the US Food and Drug Administration (“US FDA”).
  • ALS-4 is a first-in-class small molecule anti-virulence drug targeting infections caused by Staphylococcus aureus, including but not limited to Methicillin Resistant Staphylococcus Aureus (“MRSA”).
  • The Pre-IND discussions with US FDA focused on overall development plan in preparation for the IND application of ALS-4 targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI) initially.
  • With the positive feedback on the overall development strategy from the US FDA, Aptorum is now proceeding towards the IND submission of ALS-4.

Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)

Retrieved on: 
Wednesday, January 25, 2023
Standard of care, Particle-size distribution, Safety, MD, COVID-19, Pneumonia, Data monitoring committee, Teaching hospital, European Medicines Agency, Hospital, Șaeș, DSMB, S. aureus, MSSA, MRSA, Patient, VAP, Gram-positive bacteria, US, SOC, Staphylococcus aureus, LOS, EMA, Mortality, Methicillin, AES, Death, Pharmaceutical industry, ICU

The COVID-19 pandemic and the subsequent conflict in Eastern Europe limited patient enrollment from the original target sample size of 240.

Key Points: 
  • The COVID-19 pandemic and the subsequent conflict in Eastern Europe limited patient enrollment from the original target sample size of 240.
  • In the methicillin resistant S. aureus (MRSA) patients, the absolute efficacy was 28% higher than SOC alone (p=0.774).
  • The mortality due to pneumonia was: AR-301 1.6% (1/61) vs SOC 5.0% (3/59) groups among the population with confirmed S. aureus pneumonia (p=n.s.).
  • Aridis CEO Vu Truong and Dr. Jafri further discuss the Phase 3 study results in a video overview that can be viewed at: https://youtu.be/NNxqY1EkC40 .

Global Antimicrobial Resistance Diagnostics Market Report 2023: Availability of Better Diagnostics Tests and Kits Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023
Health, Biotechnology, AMR, Eyeish, Fungus, Methicillin, Subclinical infection, Bloodstream infections, DRC, Protein, Viral Research and Diagnostic Laboratories, Medication, Bacteria, Public health, Clostridium difficile, Pathogen, Immunoassay, NGS, DNA, Biotechnology, Urinary tract infection, Hospital, DRSP, Microbiology, CD, MRSA, Patient, Staphylococcus aureus, Pneumonia, Infection, Culture, Drug resistance, Catheter, Prevalence, PCR, Healthcare, Vaccine, Antibiotics, Copper

The Global Antimicrobial Resistance Diagnostics Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.

Key Points: 
  • The Global Antimicrobial Resistance Diagnostics Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.
  • Based on end user, the antimicrobial resistance diagnostics market is segmented into hospitals, diagnostic laboratories, pharmaceutical & biotechnology companies, and others.
  • The diagnostic laboratories garnered a remarkable growth rate in the antimicrobial resistance diagnostics market in 2021.
  • The North America segment procured the maximum revenue share in the antimicrobial resistance diagnostics market in 2021.